Kenneth J. O'Byrne
Princess Alexandra Hospital, BrisbaneQueensland, AustraliaAuthored Items
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
November 2018 Vol 9, NO 11
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
Last modified: September 16, 2021